Edgar Filing: AbbVie Inc. - Form 4

AbbVie Inc.											
Form 4 January 04, 20	017										
								OMB A	PPROVAL		
FORM	4 UNITED	STATES		RITIES A			COMMISSIO		3235-0287		
Check this if no longe subject to Section 16 Form 4 or Form 5	F CHAN	NGES IN SECUE	Estimated burden hou response	Expires:January 31, 2005Estimated average burden hours per response0.5							
obligation: may contin <i>See</i> Instruct 1(b).	nue. Section 17					npany Act y Act of 1	of 1935 or Secti 940	on			
(Print or Type Ro	esponses)										
1. Name and Address of Reporting Person <u>*</u> Alpern Robert J			2. Issuer Name and Ticker or Trading Symbol AbbVie Inc. [ABBV]			Trading	5. Relationship of Reporting Person(s) to Issuer				
(Last)	(First) (Middle)		of Earliest T			(Check all applicable)				
1 N. WAUKEGAN ROAD			(Month/Day/Year) 12/31/2016			X_ Director 10% Owner Officer (give title Other (specify below) below)					
(Street)			4. If Amendment, Date Original Filed(Month/Day/Year)			6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person					
NORTH CH	ICAGO, IL 600	64					Form filed by Person	More than One R	eporting		
(City)	(State)	(Zip)	Tab	le I - Non-l	Derivative	Securities A	cquired, Disposed	of, or Beneficia	lly Owned		
	. Transaction Date Month/Day/Year)	2A. Deeme Execution any (Month/Da	Date, if	3. Transactio Code (Instr. 8)	Disposed (Instr. 3, 4	(A) or of (D) and 5) (A) or	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
				Code V	Amount	(D) Price					
Reminder: Repo	rt on a separate lin	e for each cl	ass of sec	urities bene	Perso inform requir	ns who rest ation cont ed to respo ys a curre	or indirectly. Spond to the colle cained in this form ond unless the fo ntly valid OMB co	n are not rm	SEC 1474 (9-02)		

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of	2.	3. Transaction Date	3A. Deemed	4.	5. Number	6. Date Exercisable and	7. Title and Amount of	8. Pric
Derivative	Conversion	(Month/Day/Year)	Execution Date, if	Transactio	onof	Expiration Date	Underlying Securities	Deriva
Security	or Exercise		any	Code	Derivative	(Month/Day/Year)	(Instr. 3 and 4)	Securi
(Instr. 3)	Price of		(Month/Day/Year)	(Instr. 8)	Securities			(Instr.

	Derivative Security				Acqu (A) o Dispo of (D (Instr and 5	r osed) . 3, 4,					
			Сос	e V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	
Stock Equivalent Units	\$ 0 <u>(1)</u>	12/31/2016	А		104		<u>(1)</u>	<u>(1)</u>	Common Stock	104	\$ 62

Reporting Owners

Reporting Owner Name / Address		Relationsh	nips					
	Director	10% Owner	Officer	Other				
Alpern Robert J 1 N. WAUKEGAN ROAD NORTH CHICAGO, IL 60064	Х							
Signatures								
Steven L. Scrogham, attorney-in Alpern	Robert J.		01/04/2017					
<u>**</u> Signature of Reporting			Date					
Evolopation of Do	onon	0001						

Explanation of Responses:

- * If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Director fees credited to stock equivalent unit accounts under grantor trusts established by the director at Abbott Laboratories and AbbVie. The stock equivalent units in the Abbott account will be paid, in cash, generally at age 65 or upon retirement from Abbott's

- Abbvie. The stock equivalent units in the Abbvie account will be paid, in cash, generally at age 05 of upon retirement from Abbvie's board, and the stock equivalent units in the AbbVie account will be paid, in cash, generally at age 65 or upon retirement from AbbVie's board. The stock equivalent units in each account earn the same return as if the fees were invested in AbbVie stock.
- (2) Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.